Guillain–Barré Syndrome Associated with COVID-19 in a Japanese Male
Open Access
- 22 October 2022
- journal article
- case report
- Published by Hindawi Limited in Case Reports in Neurological Medicine
- Vol. 2022, 1-5
Abstract
April 2021 saw a widespread outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Osaka, Japan. We encountered the case of a 52-year-old man who had GuillainBarré syndrome associated with coronavirus disease 2019 (COVID-19). After the relief of the respiratory symptoms owing to COVID-19, the patient experienced muscle weakness, which spread from his fingers to his extremities, and was unable to walk. Further examinations revealed mild protein elevation in the cerebrospinal fluid. In addition, nerve conduction studies showed demyelinating polyneuropathy, leading to the diagnosis of GuillainBarré syndrome. After the administration of intravenous immunoglobulin and intravenous methylprednisolone, his symptoms drastically improved, and he was able to walk unaided 21 days after the onset of symptoms. On day 40, the patient was discharged with minimal muscle fatigue. Because GuillainBarré syndrome associated with COVID-19 is expected to have a good prognosis, early diagnosis and treatment are important. Therefore, GuillainBarré syndrome should be considered as a possible factor for muscle weakness during and after COVID-19 treatment.Keywords
This publication has 17 references indexed in Scilit:
- Neurological Disorders Identified during Treatment of a SARS-CoV-2 InfectionInternal Medicine, 2020
- The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findingsBrain, 2020
- Steroid‐Responsive Encephalitis in Coronavirus Disease 2019Annals of Neurology, 2020
- Regional variation of Guillain-Barré syndromeBrain, 2018
- Electrodiagnosis of reversible conduction failure in Guillain–Barré syndromeMuscle & Nerve, 2017
- Zika VirusNew England Journal of Medicine, 2016
- Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysisThe Lancet Neurology, 2011
- Bulbar involvement in patients with antiganglioside antibodies against NeuNAc( 2-3)GalJournal of Neurology, Neurosurgery & Psychiatry, 2009
- Antiganglioside antibodies and their pathophysiological effects on Guillain-Barre syndrome and related disorders--A reviewGlycobiology, 2009
- Guillain-Barré syndrome complicated with hemolytic anemia in association with antiganglioside GM3 antibodyThe American Journal of Medicine, 2001